Mynzepli syringe recall shows how a small grip variation becomes a Class 2 matter

What happened

On 29 October 2026 the MHRA issued a Class 2 medicines recall covering two batches of Mynzepli (aflibercept) 40 mg/mL solution for injection in pre-filled syringe. Advanz Pharma is carrying out the recall as a precaution. The trigger was a small variation in finger grip size on the syringes, which the company says could affect administration.

The public record is thin. The alert does not give a failure rate or a root cause, and it does not say whether any patient was affected. None of that is in the information available to us. What is clear is that the defect is mechanical and sits in the syringe, not in the aflibercept solution.

Why a grip dimension matters for quality teams

In a pre-filled syringe the device is part of the medicine. The finger grip, also called the flange, is how the user holds the syringe and controls the plunger during injection. A dimensional deviation there is not cosmetic. If it could change how the syringe is handled, it is a quality defect with a possible patient-safety link, and regulators treat it that way.

Class 2 is a mid-level recall classification. It indicates a defect that warrants action but is not the most serious category reserved for the highest-risk problems. For quality and compliance teams, the point is that no failure of the active substance is needed to start a market action. A tolerance issue on a molded plastic component is enough.

The recall also shows the value of a tight link between component suppliers and release testing. Dimensional variation in a small plastic part is the kind of issue that depends on incoming inspection, tooling control and in-process checks. The record does not say where this variation arose, so we cannot say which control, if any, failed.

A week of container and closure problems

The Mynzepli recall is one of several packaging- and device-related items from the same days. Baxter Holding B.V. has reported incomplete aluminium crimping on Caelyx 50 mg/25 ml single-dose vials. The crimping can leave a vial open when the cap is removed, with a risk to sterility and of occupational exposure. Germany's BfArM published this as a Rote-Hand-Brief, and Slovakia's ŠÚKL released a direct healthcare professional communication on the same risk. The same defect reached healthcare professionals through two national channels.

The Caelyx case differs from Mynzepli in that it involves a sterility barrier and handler exposure, not user handling. Both start with a physical closure or form defect on a primary container, and both reach clinicians through the regulatory notification system.

Elsewhere, Health Canada recalled one lot of Equate Ultra Strength Antacid Assorted Fruits chewable tablets over possible stainless steel shavings, classed Type II. That is a foreign-matter issue in an oral product, and it points back to equipment wear and contamination control. BfArM also listed urgent field safety notices from Philips (Azurion image-guided therapy system) and Intersurgical (Smoothbore Breathing System). The substance of both sits in the manufacturers' attached advisories, so we cannot describe the issues.

Who is affected and what is still unknown

The recall directly concerns the two Mynzepli batches in the UK supply chain, so wholesalers, pharmacies and clinics holding stock need to identify and quarantine affected units. The batch numbers are in the MHRA alert and should be checked there, not from secondary summaries.

Several questions remain open. We do not know the cause of the grip variation or whether other batches or markets are involved. We do not know whether any administration problems were reported, or what replacement or supply arrangements apply. Companies with similar syringe platforms may also want to ask whether the same component or tooling is shared across their products.

What to watch

Watch for any widening of the recall to other batches, and for an MHRA or company update on cause. Also watch whether other regulators publish matching notices, as happened with Caelyx across Germany and Slovakia.

The week's US Department of Justice items, covering oxycodone dispensing, Medicare Botox billing and COVID-19 test-kit fraud, are enforcement cases about prescribing, dispensing and billing. They are a separate compliance track from product quality and do not bear on the Mynzepli recall.